Miguel Aracil Selected Research

elisidepsin

3/2013	Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compound.
1/2013	Epithelial-mesenchymal transition markers and HER3 expression are predictors of elisidepsin treatment response in breast and pancreatic cancer cell lines.
7/2012	ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines.
8/2011	PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and activation of death-associated protein kinase.
7/2009	Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Miguel Aracil Research Topics

Disease

12	Neoplasms (Cancer) 12/2019 - 01/2006
3	Ovarian Neoplasms (Ovarian Cancer) 11/2021 - 01/2014
3	Sarcoma (Soft Tissue Sarcoma) 11/2016 - 04/2007
2	Ewing Sarcoma (Sarcoma, Ewing) 01/2017 - 01/2015
2	Breast Neoplasms (Breast Cancer) 11/2016 - 04/2013
1	Inflammation (Inflammations) 11/2021
1	Nausea 11/2021
1	Fatigue 11/2021
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 12/2019
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2013
1	Xeroderma Pigmentosum (Kaposi's Disease) 01/2013
1	Carcinoma (Carcinomatosis) 01/2013
1	Colorectal Neoplasms (Colorectal Cancer) 07/2012
1	Colonic Neoplasms (Colon Cancer) 07/2012
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2012
1	Lymphoma (Lymphomas) 01/2012
1	Burkitt Lymphoma (Burkitt's Lymphoma) 01/2012
1	Fibrosis (Cirrhosis) 11/2010
1	Primary Myelofibrosis (Myelosclerosis) 11/2010
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 07/2009
1	Hematologic Neoplasms (Hematological Malignancy) 04/2007
1	Infections 02/2005
1	Aplastic Anemia (Anemia, Hypoplastic) 12/2004
1	Atherosclerosis 01/2004

Drug/Important Bio-Agent (IBA)

6	TrabectedinIBA 12/2019 - 04/2013
5	elisidepsinIBA 03/2013 - 07/2009
4	Proteins (Proteins, Gene)FDA Link 01/2014 - 01/2013
3	plitidepsin (aplidine)IBA 01/2012 - 04/2007
2	liposomal doxorubicin (Doxil)FDA Link 11/2021 - 11/2016
2	PlatinumIBA 11/2021 - 11/2016
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2017 - 01/2015
2	olaparibIBA 01/2017 - 01/2015
2	Messenger RNA (mRNA)IBA 03/2013 - 01/2013
2	Pharmaceutical PreparationsIBA 01/2013 - 11/2010
1	1-dodecylpyridoxal (PLD)IBA 11/2021
1	PM 01183IBA 11/2021
1	Topotecan (Hycamtin)FDA LinkGeneric 11/2021
1	Ifosfamide FDA LinkGeneric 11/2016
1	AnthracyclinesIBA 11/2016
1	Drug CombinationsIBA 01/2015
1	1,2,3,4-tetrahydroisoquinolineIBA 10/2013
1	A-Form DNA (A-DNA)IBA 10/2013
1	UbiquitinIBA 04/2013
1	Ligases (Synthetase)IBA 04/2013
1	Biomarkers (Surrogate Marker)IBA 04/2013
1	ErbB Receptors (EGF Receptor)IBA 01/2013
1	Small Interfering RNA (siRNA)IBA 01/2013
1	Gemcitabine FDA Link 07/2012
1	Paclitaxel (Taxol)FDA LinkGeneric 07/2012
1	Cisplatin (Platino)FDA LinkGeneric 07/2012
1	Rituximab (Mabthera)FDA Link 01/2012
1	Therapeutic UsesIBA 01/2012
1	Antineoplastic Agents (Antineoplastics)IBA 01/2012
1	DepsipeptidesIBA 11/2010
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 07/2009
1	Cyclin-Dependent Kinase Inhibitor p27IBA 04/2007
1	Wiskott-Aldrich Syndrome ProteinIBA 02/2005
1	Telomerase (Telomerase Reverse Transcriptase)IBA 12/2004
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2004
1	Chemokine CCL5IBA 01/2004
1	ApolipoproteinsIBA 01/2004
1	Apolipoproteins E (ApoE)IBA 01/2004
1	Dietary CholesterolIBA 01/2004
1	Proliferating Cell Nuclear Antigen (PCNA)IBA 01/2004
1	CytokinesIBA 01/2004

Therapy/Procedure

2	Therapeutics 01/2006 - 12/2004
1	Immunomodulation 12/2019